<p>/PRNewswire/ -- LakeShore Biopharma Co., Ltd（&#34;LakeShore Biopharma&#34;或&#34;公司&#34;）（OTCPK: LSBCF; OTCPK: LSBWF），是一家全球生物製藥公司，致力於發現、開發、生產和交付新一代針對傳染病和癌症的疫苗和治療性生物製劑。今天宣佈，公司於 2026 年 2 月 4 日收到來自一個由 Oceanpine Skyline Inc.（&#34;母公司&#34;）、Oceanpine Merger Sub Inc.（&#34;合併子公司&#34;）、Oceanpine Capital Inc.、Oceanpine Investment Fund II LP、Crystal Peak Investment Inc.、Adjuvant Global Health Technology Fund, L.P.、Adjuvant Global Health Technology Fund DE, L.P.、Superstring Capital Master Fund LP、MSA GROWTH FUND II, L.P.和 Epiphron Capital (Hong Kong) Limited 組成的買方集團（&#34;買方集團&#34;）的通知，涉及公司之前宣佈的私有化交易，買方集團同意根據 2025 年 11 月 4 日公司、母公司和合並子公司之間簽署的合併協議（&#34;合併協議&#34;），以每股 0.90 美元的價格將公司私有化。</p>
<p>根據該通知，買方集團聲稱公司於 2026 年 1 月 21 日和 1 月 22 日從開封仲裁委員會收到的仲裁裁決——該裁決已在公司於 2026 年 1 月 29 日向證券交易委員會（&#34;SEC&#34;）提交的 6-K 表格當前報告中披露——以及由此產生的約人民幣 576,500,000 的財務責任構成了合併協議下的&#34;公司重大不利影響&#34;。</p>
<p>買方集團聲稱，母公司完成合並（如合併協議中定義）的前提條件是未發生公司重大不利影響（如合併協議中定義），而買方集團已確定發生了公司重大不利影響，因此買方集團有權不完成合並。買方集團表示，它將不參加或投票即將於 2026 年 2 月 12 日舉行的特別股東大會（&#34;EGM&#34;），該會議將考慮並投票通過包括授權和批准合併協議、需向開曼羣島公司註冊處提交的合併計劃及相關交易（包括合併）在內的事項。</p>
<p>買方集團表示願意與公司進行善意討論，以探索修改交易條款的可能性，以促進達成雙方都能接受的解決方案併成功完成交易。</p>
<p>鑑於這一發展，公司決定推遲之前宣佈的 EGM。已提交給公司的任何關於 EGM 的代理卡將被忽略。截止到 2026 年 1 月 16 日下午 5 點（開曼羣島時間）的股東將各自收到關於 EGM 推遲的通知。該通知也將在公司網站 https://investors.lakeshorebio.com/index.html 和 SEC 網站 http://www.sec.gov 上發佈。</p>
<p>公司將仔細審查和評估買方集團的主張及公司的選擇，並將根據適用法律的要求提供進一步的更新。</p>
<p><strong>關於 LakeShore Biopharma Co., Ltd</strong></p>
<p>LakeShore Biopharma，之前稱為 YS Biopharma，是一家全球生物製藥公司，致力於發現、開發、生產和交付新一代針對傳染病和癌症的疫苗和治療性生物製劑。它開發了專有的 PIKA®免疫調節技術平台和針對狂犬病、乙型肝炎、流感及其他病毒感染的新一代預防和治療性生物製劑。公司在中國、新加坡和菲律賓運營，由一支結合豐富本地專業知識和全球生物製藥行業經驗的管理團隊領導。</p>
<p>欲瞭解更多信息，請訪問 https://investors.lakeshorebio.com/.</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿包含可能構成 “前瞻性” 聲明的內容。這些前瞻性聲明包括但不限於公司的商業計劃和發展，可以通過諸如 “可能”、“將”、“期望”、“預期”、“目標”、“未來”、“估計”、“打算”、“計劃”、“相信”、“潛在”、“繼續”、“可能會” 等術語或其他類似表達來識別。LakeShore Biopharma 還可能在其定期向美國證券交易委員會（SEC）提交的報告、年度股東報告、新聞稿及其他書面材料中，以及其高管、董事或員工向第三方所作的口頭聲明中作出書面或口頭的前瞻性聲明。那些不是歷史事實的聲明，包括關於 LakeShore Biopharma 的信念、計劃和期望的聲明，均為前瞻性聲明。前瞻性聲明涉及固有的風險和不確定性。一些因素可能導致實際結果與任何前瞻性聲明中包含的結果存在重大差異，包括但不限於以下因素：可能出現導致合併協議終止或修訂的事件；可能會提出競爭性報價；融資可能不可用的可能性；交易的各種成交條件可能無法滿足或被放棄的可能性；以及公司向 SEC 提交的文件中討論的其他風險和不確定性，以及公司提交的 Schedule 13E-3 和代理聲明；公司的目標和戰略；公司的未來業務發展、財務狀況和經營成果；其提供高效服務和有效競爭的能力；其維護和提升品牌認知度和聲譽的能力；全球及中國的一般經濟和商業狀況，以及與上述任何內容相關的假設。有關這些及其他風險、不確定性或因素的進一步信息包含在公司向 SEC 提交的文件中。本新聞稿中提供的所有信息均截至本新聞稿的日期，公司不承擔因新信息、未來事件或其他原因而更新任何前瞻性聲明的義務，除非適用法律要求。</p>
<p><strong>如需投資者諮詢，請聯繫：</strong></p>
<p><strong>投資者關係團隊</strong> 電話：+86 (10) 8920-2086</p>
<p>電子郵件：[email protected]</p>
<p>來源：LakeShore Biopharma Co., Ltd.</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMjA2Jk5ld3NJdGVtSWQ9Q044MjQ4OCZUcmFuc21pc3Npb25fSWQ9MjAyNjAyMDYwNzAwUFJfTkVXU19VU1BSX19fX19DTjgyNDg4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMjA2Jk5ld3NJdGVtSWQ9Q044MjQ4OCZUcmFuc21pc3Npb25fSWQ9MjAyNjAyMDYwNzAwUFJfTkVXU19VU1BSX19fX19DTjgyNDg4"/></p>

LSBCF

<p>LakeShore Biopharma 收到了買方集團關於以每股 0.90 美元進行私有化交易的通知。買方集團聲稱，最近的仲裁裁決導致約 5.765 億人民幣的財務負擔，構成了 “公司重大不利影響”，使他們能夠退出合併。因此，原定於 2026 年 2 月 12 日的特別股東大會已被推遲。公司將審查這些主張，並在必要時提供更新</p>

<p>, /PRNewswire/ -- LakeShore Biopharma Co., Ltd (&#34;LakeShore Biopharma&#34; or the &#34;Company&#34;) (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it has received a notice, dated February 4, 2026, from legal counsel to a group (the &#34;Buyer Group&#34;) consisting of Oceanpine Skyline Inc. (&#34;Parent&#34;), Oceanpine Merger Sub Inc. (&#34;Merger Sub&#34;), Oceanpine Capital Inc., Oceanpine Investment Fund II LP, Crystal Peak Investment Inc., Adjuvant Global Health Technology Fund, L.P., Adjuvant Global Health Technology Fund DE, L.P., Superstring Capital Master Fund LP, MSA GROWTH FUND II, L.P., and Epiphron Capital (Hong Kong) Limited, relating to the previously announced going-private transaction of the Company whereby the Buyer Group agreed to take the Company private at a price of $0.90 per share pursuant to an Agreement and Plan of Merger (the &#34;Merger Agreement&#34;), dated November 4, 2025, by and among the Company, Parent and Merger Sub.</p>
<div class="lb-trans"><p>/PRNewswire/ -- LakeShore Biopharma Co., Ltd（&#34;LakeShore Biopharma&#34;或&#34;公司&#34;）（OTCPK: LSBCF; OTCPK: LSBWF），是一家全球生物製藥公司，致力於發現、開發、生產和交付新一代針對傳染病和癌症的疫苗和治療性生物製劑。今天宣佈，公司於 2026 年 2 月 4 日收到來自一個由 Oceanpine Skyline Inc.（&#34;母公司&#34;）、Oceanpine Merger Sub Inc.（&#34;合併子公司&#34;）、Oceanpine Capital Inc.、Oceanpine Investment Fund II LP、Crystal Peak Investment Inc.、Adjuvant Global Health Technology Fund, L.P.、Adjuvant Global Health Technology Fund DE, L.P.、Superstring Capital Master Fund LP、MSA GROWTH FUND II, L.P.和 Epiphron Capital (Hong Kong) Limited 組成的買方集團（&#34;買方集團&#34;）的通知，涉及公司之前宣佈的私有化交易，買方集團同意根據 2025 年 11 月 4 日公司、母公司和合並子公司之間簽署的合併協議（&#34;合併協議&#34;），以每股 0.90 美元的價格將公司私有化。</p>
</div><p>According to the notice, the Buyer Group asserted that the arbitral awards received by the Company from the Kaifeng Arbitration Commission on January 21 and January 22, 2026—previously disclosed in the Company's current report on Form 6-K furnished with the Securities and Exchange Commission (the &#34;SEC&#34;) on January 29, 2026—and the resulting financial liability of approximately RMB576,500,000 constitute a &#34;Company Material Adverse Effect&#34; under the Merger Agreement.</p>
<div class="lb-trans"><p>根據該通知，買方集團聲稱公司於 2026 年 1 月 21 日和 1 月 22 日從開封仲裁委員會收到的仲裁裁決——該裁決已在公司於 2026 年 1 月 29 日向證券交易委員會（&#34;SEC&#34;）提交的 6-K 表格當前報告中披露——以及由此產生的約人民幣 576,500,000 的財務責任構成了合併協議下的&#34;公司重大不利影響&#34;。</p>
</div><p>The Buyer Group asserted that a condition precedent to Parent's obligation to close the Merger (as defined in the Merger Agreement) is that no Company Material Adverse Effect (as defined in the Merger Agreement) shall have occurred, and the Buyer Group has determined that a Company Material Adverse Effect has occurred and that the Buyer Group has the right not to consummate the Merger. The Buyer Group indicated that it would not attend or cast votes at the upcoming extraordinary general meeting (the &#34;EGM&#34;), scheduled for February 12, 2026, to consider and vote on, among other matters, the proposal to authorize and approve the Merger Agreement, the plan of merger required to be filed with the Registrar of Companies of the Cayman Islands, and the transactions contemplated thereby, including the Merger.</p>
<div class="lb-trans"><p>買方集團聲稱，母公司完成合並（如合併協議中定義）的前提條件是未發生公司重大不利影響（如合併協議中定義），而買方集團已確定發生了公司重大不利影響，因此買方集團有權不完成合並。買方集團表示，它將不參加或投票即將於 2026 年 2 月 12 日舉行的特別股東大會（&#34;EGM&#34;），該會議將考慮並投票通過包括授權和批准合併協議、需向開曼羣島公司註冊處提交的合併計劃及相關交易（包括合併）在內的事項。</p>
</div><p>The Buyer Group expressed its willingness to engage in good faith discussions with the Company to explore amendments to the transaction terms to facilitate a mutually acceptable resolution and the successful completion of the transaction.</p>
<div class="lb-trans"><p>買方集團表示願意與公司進行善意討論，以探索修改交易條款的可能性，以促進達成雙方都能接受的解決方案併成功完成交易。</p>
</div><p>In light of this development, the Company has decided to postpone the previously announced EGM. Any proxy cards that have been submitted to the Company in respect of the EGM will be disregarded. Shareholders of record as of 5 p.m. Cayman Islands time on January 16, 2026 will each receive a copy of the notice regarding the postponement of the EGM. The notice will also be available on the Company's website at https://investors.lakeshorebio.com/index.html and on the SEC's website at http://www.sec.gov.</p>
<div class="lb-trans"><p>鑑於這一發展，公司決定推遲之前宣佈的 EGM。已提交給公司的任何關於 EGM 的代理卡將被忽略。截止到 2026 年 1 月 16 日下午 5 點（開曼羣島時間）的股東將各自收到關於 EGM 推遲的通知。該通知也將在公司網站 https://investors.lakeshorebio.com/index.html 和 SEC 網站 http://www.sec.gov 上發佈。</p>
</div><p>The Company will carefully review and evaluate the Buyer Group's claims and the Company's options, and will provide further updates as required under applicable law.</p>
<div class="lb-trans"><p>公司將仔細審查和評估買方集團的主張及公司的選擇，並將根據適用法律的要求提供進一步的更新。</p>
</div><p><strong>About LakeShore Biopharma Co., Ltd</strong></p>
<div class="lb-trans"><p><strong>關於 LakeShore Biopharma Co., Ltd</strong></p>
</div><p>LakeShore Biopharma, previously known as YS Biopharma, is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Hepatitis B, Influenza, and other virus infections. The Company operates in China, Singapore, and the Philippines, and is led by a management team that combines rich local expertise and global experience in the biopharmaceutical industry.</p>
<div class="lb-trans"><p>LakeShore Biopharma，之前稱為 YS Biopharma，是一家全球生物製藥公司，致力於發現、開發、生產和交付新一代針對傳染病和癌症的疫苗和治療性生物製劑。它開發了專有的 PIKA®免疫調節技術平台和針對狂犬病、乙型肝炎、流感及其他病毒感染的新一代預防和治療性生物製劑。公司在中國、新加坡和菲律賓運營，由一支結合豐富本地專業知識和全球生物製藥行業經驗的管理團隊領導。</p>
</div><p>For more information, please visit https://investors.lakeshorebio.com/.</p>
<div class="lb-trans"><p>欲瞭解更多信息，請訪問 https://investors.lakeshorebio.com/.</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This press release contains statements that may constitute &#34;forward-looking&#34; statements. These forward-looking statements include, without limitation, the Company's business plans and development, which can be identified by terminology such as &#34;may,&#34; &#34;will,&#34; &#34;expect,&#34; &#34;anticipate,&#34; &#34;aim,&#34; &#34;future,&#34; &#34;estimate,&#34; &#34;intend,&#34; &#34;plan,&#34; &#34;believe,&#34; &#34;potential,&#34; &#34;continue,&#34; &#34;is/are likely to&#34; or other similar expressions. LakeShore Biopharma may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about LakeShore Biopharma's beliefs, plans and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the possibility that events may arise that result in the termination or amendment of the Merger Agreement; the possibility that competing offers will be made; the possibility that financing may not be available; the possibility that various closing conditions for the transaction may not be satisfied or waived; and other risks and uncertainties discussed in documents filed with the SEC by the Company, as well as the Schedule 13E-3 and the proxy statement filed by the Company; the Company's goals and strategies; the Company's future business development, financial condition and results of operations; its ability to provide efficient services and compete effectively; its ability to maintain and enhance the recognition and reputation of its brands; general economic and business conditions globally and in China and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.</p>
<div class="lb-trans"><p>本新聞稿包含可能構成 “前瞻性” 聲明的內容。這些前瞻性聲明包括但不限於公司的商業計劃和發展，可以通過諸如 “可能”、“將”、“期望”、“預期”、“目標”、“未來”、“估計”、“打算”、“計劃”、“相信”、“潛在”、“繼續”、“可能會” 等術語或其他類似表達來識別。LakeShore Biopharma 還可能在其定期向美國證券交易委員會（SEC）提交的報告、年度股東報告、新聞稿及其他書面材料中，以及其高管、董事或員工向第三方所作的口頭聲明中作出書面或口頭的前瞻性聲明。那些不是歷史事實的聲明，包括關於 LakeShore Biopharma 的信念、計劃和期望的聲明，均為前瞻性聲明。前瞻性聲明涉及固有的風險和不確定性。一些因素可能導致實際結果與任何前瞻性聲明中包含的結果存在重大差異，包括但不限於以下因素：可能出現導致合併協議終止或修訂的事件；可能會提出競爭性報價；融資可能不可用的可能性；交易的各種成交條件可能無法滿足或被放棄的可能性；以及公司向 SEC 提交的文件中討論的其他風險和不確定性，以及公司提交的 Schedule 13E-3 和代理聲明；公司的目標和戰略；公司的未來業務發展、財務狀況和經營成果；其提供高效服務和有效競爭的能力；其維護和提升品牌認知度和聲譽的能力；全球及中國的一般經濟和商業狀況，以及與上述任何內容相關的假設。有關這些及其他風險、不確定性或因素的進一步信息包含在公司向 SEC 提交的文件中。本新聞稿中提供的所有信息均截至本新聞稿的日期，公司不承擔因新信息、未來事件或其他原因而更新任何前瞻性聲明的義務，除非適用法律要求。</p>
</div><p><strong>For investor inquiries, please contact:</strong></p>
<div class="lb-trans"><p><strong>如需投資者諮詢，請聯繫：</strong></p>
</div><p><strong>IR Team</strong> Tel: +86 (10) 8920-2086</p>
<div class="lb-trans"><p><strong>投資者關係團隊</strong> 電話：+86 (10) 8920-2086</p>
</div><p>Email: [email protected]</p>
<div class="lb-trans"><p>電子郵件：[email protected]</p>
</div><p>SOURCE LakeShore Biopharma Co., Ltd.</p>
<div class="lb-trans"><p>來源：LakeShore Biopharma Co., Ltd.</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMjA2Jk5ld3NJdGVtSWQ9Q044MjQ4OCZUcmFuc21pc3Npb25fSWQ9MjAyNjAyMDYwNzAwUFJfTkVXU19VU1BSX19fX19DTjgyNDg4" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=CN82488&amp;Transmission_Id=202602060700PR_NEWS_USPR_____CN82488&amp;DateId=20260206"/></p>

LakeShore Biopharma 宣佈已收到買方團體的通知，並推遲了股東特別大會